Tumor-dependent Inflammation Modulation Increases Cancer Vaccine Efficacy
|
Trainee: Rita-Marie T. Woodford |
![]() |
|
Research Mentor: Dr. Jenny Ting, PhD |
![]() |
|
Clinical Co-mentor: Dr. Karen Mckinnon, PhD |
![]() |
|
Clinical Co-mentor Dr. Jon Serody, M.D. |
|
| Home Department | Oral Biology |
| Project Description |
Summary: Our lab examines inflammation in cancer and tumor-pulsed dendritic cell vaccine efficacy. We find that tumor vaccines given to animals lacking a component of the caspase-1 activating inflammasome complex, ASC, resulted in complete reduction of tumor mass. NLRP3, a binding partner to ASC in the caspase-1 activating inflammasome complex, induces an inflammatory response at the tumor site that nonetheless inhibits T lymphocytes from killing tumor cells. This immune suppression is correlated with an increase of a population of cells called Myeloid-derived suppressor cells (MDSC).
|



